Chemical Component Summary | |
---|---|
Name | Quinidine |
Synonyms | (9S)-6'-methoxycinchonan-9-ol |
Identifiers | (S)-[(1S,2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol |
Formula | C20 H24 N2 O2 |
Molecular Weight | 324.417 |
Type | NON-POLYMER |
Isomeric SMILES | COc1ccc2c(c1)c(ccn2)[C@@H]([C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)O |
InChI | InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-/m0/s1 |
InChIKey | LOUPRKONTZGTKE-LHHVKLHASA-N |
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 48 |
Chiral Atom Count | 5 |
Bond Count | 51 |
Aromatic Bond Count | 11 |
Drug Info: DrugBank
DrugBank ID | DB00908 |
---|---|
Name | Quinidine |
Groups |
|
Description | Quinidine is a D-isomer of [quinine] present in the bark of the Cinchona tree and similar plant species. This alkaloid was first described in 1848 and has a long history as an antiarrhythmic medication.[A38016,A250050] Quinidine is considered the first antiarrhythmic drug (class Ia) and is moderately efficacious in the acute conversion of atrial fibrillation to normal sinus rhythm.[A38016] It prolongs cellular action potential by blocking sodium and potassium currents. A phenomenon known as “quinidine syncope” was first described in the 1950s, characterized by syncopal attacks and ventricular fibrillation in patients treated with this drug.[A38016] Due to its side effects and increased risk of mortality, the use of quinidine was reduced over the next few decades. However, it continues to be used in the treatment of Brugada syndrome, short QT syndrome and idiopathic ventricular fibrillation.[A250050] |
Synonyms |
|
Brand Names |
|
Indication | Quinidine is indicated for the management and prophylactic therapy of atrial fibrillation/flutter, as well as the suppression of recurrent documented ventricular arrhythmias.[L42420,L3719] It is also used in the treatment of Brugada syndrome, short QT syndrome and idiopathic ventricular fibrillation.[A250050,A250055]. |
Categories |
|
ATC-Code |
|
CAS number | 56-54-2 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Sodium channel protein type 5 subunit alpha | MANFLLPRGTSSFRRFTRESLAAIEKRMAEKQARGSTTLQESREGLPEEE... | unknown | inhibitor |
Potassium channel subfamily K member 1 | MLQSLAGSSCVRLVERHRSAWCFGFLVLGYLLYLVFGAVVFSSVELPYED... | unknown | inhibitor |
Potassium channel subfamily K member 6 | MRRGALLAGALAAYAAYLVLGALLVARLEGPHEARLRAELETLRAQLLQR... | unknown | inhibitor |
Potassium voltage-gated channel subfamily H member 2 | MPVRRGHVAPQNTFLDTIIRKFEGQSRKFIIANARVENCAVIYCNDGFCE... | unknown | inhibitor |
Alpha-1A adrenergic receptor | MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILS... | unknown | antagonist |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL1294 |
PubChem | 441074 |
ChEMBL | CHEMBL1294 |
ChEBI | CHEBI:28593 |
CCDC/CSD | BOMDUC, MUHZUM, JEYZIX, QUINDE |
COD | 4102233, 2212613 |